Asthma pharmacotherapy

Otolaryngologic Clinics of North America

Volumn 47, Issue 1, 2014, Pages 55-64

  Schofield, Minka L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Anti IgE therapy; Asthma; Inhaled corticosteroids; Long acting beta agonists; Medications; Short acting beta agonists; Therapy

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LEVALBUTEROL; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL; OMALIZUMAB; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; ZILEUTON;

ALLERGIC ASTHMA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DYSPHONIA; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; MACROPHAGE; MILD PERSISTENT ASTHMA; PARTICLE SIZE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; SEVERE PERSISTENT ASTHMA; SINUSITIS; SKIN TOXICITY; THRUSH; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTI-IGE THERAPY; ASTHMA; INHALED CORTICOSTEROIDS; LONG ACTING BETA AGONISTS; MEDICATIONS; SHORT ACTING BETA AGONISTS; THERAPY;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84888851498     PISSN: 00306665     EISSN: 15578259     Source Type: Journal    
DOI: 10.1016/j.otc.2013.09.011     Document Type: Review

References (32)

1. National Asthma Education and Prevention Program Expert panel report 3: guidelines for the diagnosis and management of asthma 2007, NIH Publication, 07-4051.
2. Cazzola M., Page C.P., Rogliani P., et al. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013, 187(7):690-696.
3. Castle W., Fuller R., Hall J., et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993, 306:1034-1037.
4. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26.
5. Mann M., Chowdhury B., Sullivan E., et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003, 124:70-74.
6. Chowdhury B.A., Dal Pan G. The FDA and safe use of long acting beta agonists in the treatment of asthma. NEngl J Med 2010, 362:1169-1171.
7. Lasserson T.J., Ferrara G., Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2011, (12). CD004106.
8. Aalbers R., Brusselle G., McIver T., et al. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/sameterol in an open-label, randomized study. Adv Ther 2012, 29(11):958-969.
9. Hojo M., Mizutani T., Iikura M., et al. Asthma control can be maintained after fixed-dose, budesonide/formoterol combination inhaler therapy is stepped down from medium to low dose. Allergol Int 2013, 62:91-98.
10. Kerstjens H.A., Engel M., Dahl R., et al. Tiotropium in asthma poorly controlled with standard combination therapy. NEngl J Med 2012, 367:1198-1207.
11. Townley R.G., Suliaman F. The mechanism of corticosteroids in treating asthma. Ann Allergy 1987, 58(1):1-6.
12. Jang A. Steroid response in refractory asthmatics. Korean J Intern Med 2012, 27:143-148.
13. Lawrence M., Wolfe J., Webb D.R., et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med 1997, 156:744-751.
14. Leach C., Colice G.L., Luskin A.C. Particle size of inhaled corticosteroids: does it matter?. JAllergy Clin Immunol 2009, 124(Suppl 6):S88-S93.
15. van den Berge M., ten Hacken N.H., van der Wiel E., et al. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy 2013, 68:16-26.
16. Kramer S., Rottier B.L., Scholten R.J., et al. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2013, (2). CD010352.
17. Leach C.L., Kuehl P.J., Ramesh C., et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydroflouroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012, 108:135-200.
18. Chauhan B.F., Chartrand C., Ducharme F.M. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013, (2). CD009611.
19. Rank M.A., Hagan J.B., Park M.A., et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized control trials. JAllergy Clin Immunol 2013, 131:724-729.
20. Chauhan B.F., Ducharme F.M. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012, (5). CD002314.
21. Netzer N.C., Küpper T., Voss H.W., et al. The actual role of sodium cromoglycate in the treatment of asthma-a critical review. Sleep Breath 2012, 16:1027-1032.
22. Pelaia G., Gallelli L., Renda T., et al. Update on optimal use of omalizumab in management of asthma. JAsthma Allergy 2011, 4:49-59.
23. Hanania N.A., Alpan O., Hamilos D.L., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154(9):573-582.
24. Kim J.M., Lin S.Y., Suarez-Cuervo C., et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics 2013, 131:1155-1167.
25. Beeh K., Kanniess F., Wagner F., et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. JAllergy Clin Immunol 2013, 131:866-874.
26. Chang C. Asthma in children and adolescents: a comprehensive approach to diagnosis and management. Clin Rev Allergy Immunol 2012, 43:98-137.
27. Hansbro P.M., Scott G.V., Essilfie A., et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Investig Drugs 2013, 22(1):49-69.
28. Ingram J.L., Krat M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. JAllergy Clin Immunol 2012, 130:829-842.
29. Pavord I.D., Korn S., Howarth P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial. Lancet 2012, 380:651-659.
30. Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. JAllergy Clin Immunol 2013, 131:636-645.
31. Lipworth B.J., Basu K., Donald H.P., et al. Tailored second line therapy in asthmatic children with the Arg 16 genotype. Clin Sci (Lond) 2013, 124:521-528.
32. Iordanidou M., Paraskakis E., Tavridou A., et al. G894T polymorphism of eNOS gene is a predictor of response t combination of inhaled corticosteroids with long-lasting β2- agonist in asthmatic children. Pharmacogenomics 2012, 13(12):1363-1372.